Drug Trial Radar · NCT03066648
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
241
Actual
Start
Jul 6, 2017
Primary completion
Sep 8, 2023
Study completion Sep 8, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients, and to identify recommended doses for future studies.
Conditions
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Preleukemia
- Bone Marrow Diseases
- Hematologic Diseases
- Chronic Myelomonocytic Leukemia
Interventions
DecitabineDrug
Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
PDR001Drug
PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
MBG453Drug
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
AzacitidineDrug
Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of MBG453 single agent treatment or MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine or azacitidine.Time frame: 24 months
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: 2 months
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: 1 month
- Tolerability of MBG453 single agent treatment or MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine or azacitidine.Time frame: 24 months
Locations
11 sites in 8 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Oregon Health Sciences University Main Center
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Cardiff, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.